Drug Trial Radar · NCT07076095
A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Jul 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Aug 1, 2025
Primary completion
Aug 1, 2028
Study completion Aug 1, 2031
Sponsor
- Lead sponsor
- SUNHO(China)BioPharmaceutical CO., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Zhengzhou University
- First posted
- Jul 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was designed to compare the efficacy and safety of IBB0979 in combination with topotecan versus topotecan in subjects with relapsed small cell lung cancer (SCLC).
Conditions
- Small Cell Lung Cancer
Interventions
IBB0979Drug
bifunctional antibody-cytokine fusion protein that targets B7-H3 and IL-10 receptor
topotecan hydrochloride for injectionDrug
Topotecan hydrochloride will be administered intravenously per prescribing information.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of adverse events (AEs) and SAEs (Phase II)Time frame: Approximately within 36 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.